title: Regulatory aspects of noninvasive glucose measurements.
abstract: The Medical Device Amendments of 1976 to the Federal Food, Drug, and Cosmetic Act (the Act) established three regulatory classes for medical devices. Section 513 of the Act specifies three classes based upon the degree of control and Food and Drug Administration (FDA) oversight that is necessary to assure that the various types of devices are safe and effective. High-risk devices are placed into the most regulated device class, Class III. Under Section 515 of the Act, all devices placed in Class III are subject to premarket approval (PMA) requirements. PMA by FDA is the required process of scientific review to ensure the safety and effectiveness of Class III devices. Advisory panel review is required of virtually all original submissions. Manufacturing facilities of devices requiring PMA approval are also subject to preapproval inspection to assure data integrity and compliance with good manufacturing practices. An approved PMA is granted for marketing a particular medical device for a particular intended use. FDA considers noninvasive and minimally invasive glucose devices that are intended to measure, monitor, or predict blood glucose levels in diabetics to be high-risk medical devices. These devices will have a significant potential impact on the medical care of people with diabetes. The technology offers potential improvements in the quality of life, enhanced blood glucose control through increased frequency of testing, or access to testing, in a broader range of patients. However, the technology is not yet well understood, and the information obtained from these devices is often different from the information that has been the traditional base for the management of diabetes. As a result, FDA requires both analytical and clinical studies to support the intended claims for these new devices.
authors.affiliation: Center for Devices and Radiologic Health, Rockville, Maryland 20855, USA.
authors.forename: Steve
authors.initials: S
authors.lastname: Gutman
authors.forename: Patricia
authors.initials: P
authors.lastname: Bernhardt
authors.forename: Arleen
authors.initials: A
authors.lastname: Pinkos
authors.forename: Marva
authors.initials: M
authors.lastname: Moxey-Mims
authors.forename: Thomas
authors.initials: T
authors.lastname: Knott
authors.forename: Jean
authors.initials: J
authors.lastname: Cooper
mesh_terms: D001786:Blood Glucose / Q000032:analysis*; D018795:Device Approval; D004704:Endocrinology / Q000295:instrumentation* / Q000379:methods; D004864:Equipment and Supplies; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001786:Blood Glucose